R Oklahoma House · District 95 On the 2026 ballot

Rep. Max Wolfley

Contact Email Phone Official site ↗

Compare

Session

Total votes

6,170

all sessions

Attendance

98%

99 missed

Higher than 84% of chamber peers

With party

93%

of cast votes

Lower than 82% of chamber peers

Bipartisan score

4%

crosses aisle rarely

Higher than 80% of chamber peers

Voting record

Yea

5,556

voted in favor

Nay

514

voted against

Absent

99

missed votes

Total cast

6,170

across all sessions

Crossed party

406

votes against own party

This page

6,170

matching current filters

Bill

Description

Vote

Result

Tally

Date

HB 4486

State Capitol Preservation Commission; monument; emergency.

Yea

Passed

88–0

Mar 11, 2026

HB 4342

Civil procedure; admissibility; evidence; disclosure; term; effective date.

Yea

Passed

91–0

Mar 11, 2026

HB 3880

Tourism; commissions from tourism magazine and digital prints; additional employee compensation; effective date. Against party

Nay

Passed

60–31

Mar 11, 2026

HB 2206

Retirement; Law Enforcement Retirement System; defining term; participation; emergency.

Yea

Passed

91–0

Mar 11, 2026

HB 3040

Crimes and punishments; expanding zone of safety to include certain places; effective date.

Yea

Passed

86–5

Mar 11, 2026

HB 2961

Higher education; TSgt Marshal Dakota Roberts Gold Star Survivor Act; career and technology education; waiver of tuition and fees for the spouse and children of a Gold Star recipient; effective date.

Yea

Passed

90–0

Mar 11, 2026

HB 4432

Revenue and taxation; adjustments; eliminating limitation on itemization of wagering losses for certain tax years; effective date. Against party

Nay

Passed

70–15

Mar 11, 2026

HB 4317

Professions and occupations; accountants; education requirements; certificates; effective date.

Yea

Passed

83–0

Mar 11, 2026

HB 3930

Service animals; definition; written notice; fines; effective date.

Yea

Passed

73–14

Mar 11, 2026

HB 3834

Ibogaine clinical trials; Oklahoma Breakthrough Therapy Act; terms; requirements for drug developers; contractual terms; intellectual property rights; reports; intellectual property account; effective date.

Yea

Passed

68–23

Mar 11, 2026